The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.
Male or female Chinese participants aged 9 years or older at the screening visit.
A minimum of 20 inflammatory lesions and 25 non-inflammatory lesions on the face at Screening and Baseline.
Facial acne vulgaris severity grade 3 (moderate) on the IGA scale at Screening and Baseline.
A minimum of 20 inflammatory lesions and 20 non-inflammatory lesions but no more than 100 non-inflammatory lesion counts on the trunk (shoulders, upper back, and upper anterior chest) reachable for self-application of investigational product by the participant at Screening and Baseline (optional criterion for participant between 9 and 11 years of age).
Pregnant women (positive serum pregnancy test result at the screening visit or positive UPT at the baseline visit), breastfeeding women, or women planning a pregnancy during the study or within 1 month after the last investigational product application.
Severe forms of acne (e.g., acne conglobata, acne fulminans) or secondary acne form (e.g., chloracne, drug-induced acne) at the screening and baseline visits.
More than 1 nodule on the face at the screening and baseline visits.
More than 1 nodule on the trunk at the screening and baseline visits.